Last reviewed · How we verify
Teicoplanin antimicrobial-lock solution
Teicoplanin antimicrobial-lock solution is a Glycopeptide antibiotic Small molecule drug developed by Clinica Universidad de Navarra, Universidad de Navarra. It is currently FDA-approved for Prevention and treatment of central venous catheter-related bloodstream infections, Catheter lock therapy for hemodialysis and parenteral nutrition catheters. Also known as: teicoplanin: targocid 200 mg vial., sodium heparin 1%, 5000 IU/5ml., sodium chloride 0,9% 10 ml vial..
Teicoplanin is a glycopeptide antibiotic that inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors.
Teicoplanin is used as an antimicrobial-lock solution to prevent or treat catheter-related infections and bacteremia. The exact mechanism of action of Teicoplanin is unknown.
At a glance
| Generic name | Teicoplanin antimicrobial-lock solution |
|---|---|
| Also known as | teicoplanin: targocid 200 mg vial., sodium heparin 1%, 5000 IU/5ml., sodium chloride 0,9% 10 ml vial. |
| Sponsor | Clinica Universidad de Navarra, Universidad de Navarra |
| Drug class | Glycopeptide antibiotic |
| Target | Bacterial peptidoglycan (D-Ala-D-Ala) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Teicoplanin works by preventing cross-linking of peptidoglycan strands in the bacterial cell wall, leading to cell wall instability and bacterial death. When used as an antimicrobial-lock solution, it is instilled into central venous catheters to prevent and treat catheter-related bloodstream infections by maintaining high local antibiotic concentrations at the catheter tip.
Approved indications
- Prevention and treatment of central venous catheter-related bloodstream infections
- Catheter lock therapy for hemodialysis and parenteral nutrition catheters
Common side effects
- Local catheter site reactions
- Fever
- Thrombophlebitis
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Teicoplanin antimicrobial-lock solution CI brief — competitive landscape report
- Teicoplanin antimicrobial-lock solution updates RSS · CI watch RSS
- Clinica Universidad de Navarra, Universidad de Navarra portfolio CI
Frequently asked questions about Teicoplanin antimicrobial-lock solution
What is Teicoplanin antimicrobial-lock solution?
How does Teicoplanin antimicrobial-lock solution work?
What is Teicoplanin antimicrobial-lock solution used for?
Who makes Teicoplanin antimicrobial-lock solution?
Is Teicoplanin antimicrobial-lock solution also known as anything else?
What drug class is Teicoplanin antimicrobial-lock solution in?
What development phase is Teicoplanin antimicrobial-lock solution in?
What are the side effects of Teicoplanin antimicrobial-lock solution?
What does Teicoplanin antimicrobial-lock solution target?
Related
- Drug class: All Glycopeptide antibiotic drugs
- Target: All drugs targeting Bacterial peptidoglycan (D-Ala-D-Ala)
- Manufacturer: Clinica Universidad de Navarra, Universidad de Navarra — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Prevention and treatment of central venous catheter-related bloodstream infections
- Indication: Drugs for Catheter lock therapy for hemodialysis and parenteral nutrition catheters
- Also known as: teicoplanin: targocid 200 mg vial., sodium heparin 1%, 5000 IU/5ml., sodium chloride 0,9% 10 ml vial.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing